ClinicalTrials.gg
RecruitingNCT07351643DAPA-PCATUpdated Oct 30, 2026

CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes Patients With Stage 4 CKM Syndrome

A Phase 4 interventional study of Dapagliflozin in ACS (Acute Coronary Syndrome) and SGLT2 Inhibitors, sponsored by Shenyang Northern Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-30.

Sponsored by Shenyang Northern Hospital · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Oct 30, 2026Now RecruitingSite recruiting status changed+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital — 5 open to participants now, 5 under way, none of them phase 3. Acute Coronary Syndrome · Shenyang Northern Hospital.

Started
2026
with 2 others
Phase 4
8 of 12
2 open now
Registered
10th of 12
by date

Among the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, this one is one of 3 that started in 2026, is one of 8 in phase 4, and was the 10th registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

5 of the 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Acute Coronary Syndrome by Shenyang Northern Hospital, or all of them as a file.
02

Study summary

The aim of this clinical trial is to investigate whether dapagliflozin (a sodium-glucose cotransporter 2 inhibitor, SGLT2i) can reduce levels of coronary inflammation in patients with stage 4 CKM syndrome.

Coronary inflammation will be measured using the fat attenuation index (FAI), a marker derived from coronary CT angiography (CCTA) that quantifies inflammation in the fat tissue surrounding heart arteries.

The main questions it aims to answer are

  • Does dapagliflozin lower coronary artery inflammation as measured by FAI?
  • Does dapagliflozin slow the progression of coronary plaques?

Researchers will compare participants who take dapagliflozin 10 mg daily plus standard therapy to those who receive standard therapy alone for 6 months.

Participants will:

  • Undergo percutaneous coronary intervention (PCI) for ACS
  • Have a baseline CCTA scan at 1 month after PCI, at which point they will be randomly assigned to receive dapagliflozin or standard care alone.
  • Have a follow-up CCTA scan at 6 months after randomisation.
  • Receive follow-up phone calls at 3 and 6 months after randomisation
Read the detailed description

Patients with stage 4 CKM syndrome are individuals who have at least one of excessive/dysfunctional adiposity, other CKM-related risk factors, or chronic kidney disease (CKD), complicated by clinical cardiovascular disease (CVD), including coronary artery disease, heart failure, stroke, peripheral arterial disease, and atrial fibrillation. Stage-4 CKM patients carry an extremely high risk of adverse clinical outcomes. Nearly 80 % of adults in China are at stage 1 or higher of CKM syndrome, among whom patients at stage 4 exhibit a 4-fold higher mortality risk compared with those at stage 0. Representing a very-high-risk population, they are in urgent need of targeted interventions.

Chronic inflammation constitutes the core pathological mechanism underlying CKM progression. Circulating inflammatory biomarkers currently lack sufficient specificity, while PET-CT is costly and poorly accessible, limiting its clinical utility. Studies have demonstrated that fat attenuation index (FAI), calculated by analyzing the radiodensity of pericoronary adipose tissue (PCAT) derived from coronary computed-tomographic angiography (CCTA), enables non-invasive quantification of coronary inflammation. In the setting of arterial inflammation, PCAT loses lipid content with an elevated water-to-lipid ratio, shifting FAI from the lipid-rich phase (approximately -190 HU) toward the water-rich phase (approximately -30 HU). As a novel surrogate inflammatory biomarker, PCAT holds promise as a new therapeutic target for cardiovascular diseases.

Beyond their glucose-lowering and diuretic effects, sodium-glucose cotransporter 2 inhibitors (SGLT2is) exert anti-inflammatory properties, including suppression of inflammatory-cytokine expression and mitigation of oxidative stress. They also reduce the thickness and volume of epicardial adipose tissue (EAT) and dampen its secretion of inflammatory cytokines, which may represent an important pathway mediating their cardiovascular benefits. Nevertheless, existing studies enroll relatively homogeneous populations and do not cover the high-risk stage-4 CKM cohort. Patients with stage-4 CKM have greater EAT burden, and EAT contributes to disease progression. Accordingly, leveraging photon-counting CT, this study aims to explore the modulatory effect of 6-month SGLT2i therapy on local coronary inflammation in stage-4 CKM patients, as well as the association between clinical benefits and alleviated coronary inflammation, so as to provide theoretical evidence for targeted anti-inflammatory therapy in this patient population.

03

Conditions studied

  • ACS (Acute Coronary Syndrome)
  • SGLT2 Inhibitors

Keywords

  • Fat attenuation index
  • SGLT2 inhibitors
  • Pericoronary adipose tissue
  • Residual inflammatory risk
  • Coronary CT angiography
04

Who can participate

The criteria were revised on the registry on Oct 30, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Aged ≥ 18 years, irrespective of gender;
  2. Meeting the diagnostic criteria for stage 4 CKM syndrome;
  3. Able to cooperate with photon-counting CT examination during the index hospitalisation, with no to the examination;
  4. Signed form.

Exclusion criteria

Exclusion Criteria

  1. Receiving SGLT2 inhibitor therapy within 4 weeks prior to enrolment;
  2. Severe hepatic dysfunction ( class C);
  3. History of recurrent urogenital tract infections;
  4. History of allergy or intolerance to SGLT2 inhibitors;
  5. Pregnant or lactating women;
  6. Systolic blood pressure \< 90 mmHg and/or diastolic blood pressure \< 60 mmHg;
  7. Severe chronic kidney disease ( \< 30 mL/min/1.73 m²);
  8. Participation in other interventional clinical trials;
  9. Other conditions deemed inappropriate for enrolment by the investigator(s).
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Dapagliflozin group

    Participants receive dapagliflozin 10 mg orally once daily in addition to guideline-directed medical therapy for 6 months.

    Drug: Dapagliflozin

  • No intervention
    Non-dapagliflozin group

    Participants receive guideline-directed medical therapy alone without any SGLT2 inhibitor for 6 months.

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in FAI from baseline to 6 months in patients assessed by CCTA

    Change in FAI of major coronary arteries (left main \[LM\], right coronary artery \[RCA\], left anterior descending \[LAD\], and left circumflex \[LCX\]) from baseline to 6 months, expressed in Hounsfield Units (HU), assessed at the patient level.

    Time frame: From randomization to 6 months post-randomization

Secondary outcomes

  1. Change in total plaque volume

    Absolute change in total coronary plaque volume (mm³)

    Time frame: From randomization to 6 months post-randomization

  2. Change in calcified plaque volume

    Absolute change in calcified plaque volume (mm³)

    Time frame: From baseline (at randomization) to 6 months post-randomization

  3. Change in fibrous plaque volume

    Absolute change in fibrous plaque volume (mm³)

    Time frame: From baseline (at randomization) to 6 months post-randomization

  4. Change in fibrofatty plaque volume

    Absolute change in fibrofatty plaque volume (mm³)

    Time frame: From baseline (at randomization) to 6 months post-randomization

  5. Change in low-attenuation plaque volume

    Absolute change in low-attenuation plaque volume (mm³)

    Time frame: From baseline (at randomization) to 6 months post-randomization

  6. Change in coronary stenosis

    Absolute change in degree of coronary artery stenosis (%)

    Time frame: From baseline (at randomization) to 6 months post-randomization

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.

Of 85 non-industry phase 4 interventional studies under Acute Coronary Syndrome, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 67. This study's planned 12 months is below that.

Counting every sponsor, half of 92 studies reached it within 42 months; a quarter within 26 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 30, 2026: start Feb 2026 → Jun 2026, primary completion Oct 2026 → Jun 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 12, 2026
First posted
Jan 20, 2026
StartActual
Jun 25, 2026was Feb 2026
Primary completionEst.
Jun 30, 2027was Oct 2026
CompletionEst.
Jun 30, 2027was Dec 2026
Last update
Oct 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 30, 2026
Sites
General Hospital of Northern Theater Command is now Recruiting
Oct 30, 2026
Start date
Feb 25, 2026→Jun 25, 2026 (actual)
Oct 30, 2026
Primary completion
Oct 30, 2026→Jun 30, 2027
Oct 30, 2026
Study completion
Dec 30, 2026→Jun 30, 2027
Oct 30, 2026
Eligibility
4 inclusion criteria added, 5 removed; 6 exclusion criteria edited, 1 added, 3 removed
What changed in the criteria
Inclusion criteria
  • RemovedAge ≥18 years
  • RemovedDiagnosis of acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina)
  • RemovedUndergoing percutaneous coronary intervention (PCI)
  • RemovedPresence of multivessel coronary artery disease with at least one non-culprit vessel not undergoing revascularization (for CCTA follow-up assessment)
  • RemovedWilling and able to provide written informed consent
  • AddedAged ≥ 18 years, irrespective of gender;
  • AddedMeeting the diagnostic criteria for stage 4 CKM syndrome;
  • AddedAble to cooperate with photon-counting CT examination during the index hospitalisation, with no contraindications to the examination;
  • AddedSigned informed consent form.
Exclusion criteria
  • RemovedPrior or current diagnosis of diabetes mellitus
  • RemovedPrior or current diagnosis of chronic heart failure
  • EditedTreatment with anyReceiving SGLT2 inhibitor therapy within 4 weeks prior to enrollmentenrolment;
  • ChangedBefore Severe hepatic impairmentNow Severe hepatic dysfunction (Child-Pugh class C);
  • EditedHistory of recurrent urogenital tract infections;
  • EditedKnownHistory of allergy or intolerance to SGLT2 inhibitors;
  • ChangedBefore Pregnancy or breastfeedingNow Pregnant or lactating women;
  • EditedCurrent participationParticipation in anotherother interventional clinical trialtrials;
  • RemovedAny other condition that, in the opinion of the investigator, would make the participant unsuitable for enrollment
  • AddedOther conditions deemed inappropriate for enrolment by the investigator(s).
Oct 30, 2026
Title
CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HFWith Stage 4 CKM Syndrome
Oct 30, 2026
Show all 1 update
  1. Oct 30, 2026
    Not yet recruiting→Recruiting
    General Hospital of Northern Theater Command is now Recruiting
    Start date Feb 25, 2026→Jun 25, 2026 (now actual)
    Primary completion Oct 30, 2026→Jun 30, 2027
    Study completion Dec 30, 2026→Jun 30, 2027
    Eligibility 4 inclusion criteria added, 5 removed; 6 exclusion criteria edited, 1 added, 3 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedAge ≥18 years
    • RemovedDiagnosis of acute coronary syndrome (including ST-elevation myocardial infarction, non-ST-elevation myocardial infarction, or unstable angina)
    • RemovedUndergoing percutaneous coronary intervention (PCI)
    • RemovedPresence of multivessel coronary artery disease with at least one non-culprit vessel not undergoing revascularization (for CCTA follow-up assessment)
    • RemovedWilling and able to provide written informed consent
    • AddedAged ≥ 18 years, irrespective of gender;
    • AddedMeeting the diagnostic criteria for stage 4 CKM syndrome;
    • AddedAble to cooperate with photon-counting CT examination during the index hospitalisation, with no contraindications to the examination;
    • AddedSigned informed consent form.
    Exclusion criteria
    • RemovedPrior or current diagnosis of diabetes mellitus
    • RemovedPrior or current diagnosis of chronic heart failure
    • EditedTreatment with anyReceiving SGLT2 inhibitor therapy within 4 weeks prior to enrollmentenrolment;
    • ChangedBefore Severe hepatic impairmentNow Severe hepatic dysfunction (Child-Pugh class C);
    • EditedHistory of recurrent urogenital tract infections;
    • EditedKnownHistory of allergy or intolerance to SGLT2 inhibitors;
    • ChangedBefore Pregnancy or breastfeedingNow Pregnant or lactating women;
    • EditedCurrent participationParticipation in anotherother interventional clinical trialtrials;
    • RemovedAny other condition that, in the opinion of the investigator, would make the participant unsuitable for enrollment
    • AddedOther conditions deemed inappropriate for enrolment by the investigator(s).
    Title CCTA Evaluation of SGLT2i-related Pericoronary Fat Changes in Non-diabetic ACS Patients Without HFWith Stage 4 CKM Syndrome
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07351643
Lead sponsor
Shenyang Northern Hospital
Responsible party
Han Yaling (Prof., Shenyang Northern Hospital) — Principal investigator
First posted
Jan 20, 2026
Start date
Jun 25, 2026
Primary completion
Jun 30, 2027 (estimated)
Completion
Jun 30, 2027 (estimated)
Last update
Oct 30, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dapagliflozin

Start the discussion